Dyne Therapeutics Introduces Breakthrough DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics has introduced DYNE-251 as an investigational therapy that has received FDA Breakthrough Therapy Designation for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping.
DYNE-251 is designed as a phosphorodiamidate morpholino oligomer (PMO) conjugated to an antibody fragment that binds to the transferrin receptor 1, enabling targeted delivery to skeletal and cardiac muscle. It focuses on exon 51 of the dystrophin gene with the aim of restoring near full-length dystrophin production, a protein critical for muscle strength and function, and slowing disease progression in people living with DMD51.
The FDA’s Breakthrough Therapy designation recognises the potential of DYNE-251 to deliver meaningful clinical benefits in this population. The therapy has also been granted Fast Track, Orphan Drug and Rare Paediatric Disease designations in the United States, as well as Orphan Drug designation from the European Medicines Agency (EMA).
Duchenne muscular dystrophy is a rare, progressive genetic disorder caused by mutations in the dystrophin gene. It results in severe muscle weakness, loss of mobility, and progressive involvement of the heart and respiratory system. The condition primarily affects boys and is usually identified in early childhood.
DYNE-251 is the 'first-and-only' investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of Duchenne muscular dystrophy in individuals with mutations amenable to exon 51 skipping (DMD51).
